Download - 20160126 smb avivia hans platteeuw
Avivia History
• In 2005 Avivia started as a one-man company focussing on providing consultancy services in pharmaceutical product development
• In 2007 the company was restructured into a limited liability company and the first personnel was hired
• In 2010 the decision was taken to scale down the consultancy business and start investing in our own ideas and on setting up joint ventures with other SME-companies
The opportunity to take the next step
• In 2013, Synthon announced that it would close down its small molecule development activitities in Nijmegen, The Netherlands
• Several people saw this as an opportunity to make the change from being an employee to becoming an entrepeneur
• In 2014, we started working together and through SMB we hired a business consultant, Peter van de Laarse, to advice us on how best to setup a combined business
Getting the basics right for Avivia 2.0
• Avivia 2.0 is a merger between 3 new one-man companies with an inventory of equipment and an established company with a network, running business and development projects
• Main issues that needed to be adressed: - what assets does each individual company bring to the table
- what is the value of those assets within the new company
- how does that translate into the total value of the company and the distribution of shares
- what is the optimal legal and fiscal setup for the new company
- who will lead the new company
- financial forecast and business plan (with a 7-year horizon)
- we have setup the control systems for our business, like the financial, project and contract administration and time allocation
• Avivia 2.0 was legally formed on the 14th of July, 2015
Avivia Team
Slide
5
Within Avivia we have the capabilities and the
expertise to develop any pharmaceutical drug
product from scratch to cGMP
Menno Wiltink
Synthon
Analytical development
Hans Platteeuw
Synthon, Dafra, Avivia
Managing Director Dennie van den Heuvel
Intervet, Synthon
Pharmaceutical Development
Hans van der Steen
CP Kelco, Synthon
Analytical Research
Thomas Verbeek
AUV veterinary
services
Controller
Marleen De Vriese
Dafra, Avivia
Project Manager
Avivia Professional Panel
Slide
6
In our operations we have close ties with a number
of professionals that work with us on a daily
basis in various aspects of our business.
Wout Wouters
Solvay, TNO, Pantarhei
In vitro testing and in
vivo animal studies
Han van ‘t Klooster
Pharmacytics, Chamaeleo
Business developmentLaurens Theunis
Galapagos, Formac, Chamaeleo
Investment manager
Frank Vanderdonck
Pfizer, UCB, Ipsen,
Chamaeleo
Business Intelligence/Medical
Liaison Peter van de Laarse
PWC, Belastingdienst
Business Consultant
Gelein Platteeuw
Intervet/MSD
Facilities/Procurement
Avivia business
• Avivia has developed a number of opportunities for repurposingof existing drugs in various clinical fields, e.g. GastrointestinalInflammation, Womens’ Health, Oncology and Tropical Diseases
• We currently have 2 products in a screening stage, 3 in feasilibity and 4 in proof of concept testing (phase II clinical testing in patients/volunteers)
• We are also open for other companies to support them in their product developments, either as a pure fee for service (contract research) or in co-development deals
Slide
7
Avivia within 5 years
• Within 5 years aim to become a flexible, dedicated, creative pharmaceutical product innovation company with a focus on drug repurposing programs
• We expect to employ 20-25 people and have an annual turnover of at least 10 million Euro
For more information, please contact:
9
Hans Platteeuw
Van Leeuwenhoekweg 12
5482 TK Schijndel
The Netherlands
Mobile: + 31 6 286 75 973
E-mail: [email protected]
Skype: hans.platteeuw